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Clinical evaluation of the MacuScope macular
pigment densitometer
Hannah Bartlett, Jennifer Acton, Frank Eperjesi
ABSTRACT
Background/aims The MacuScope uses
a psychophysical technique called heterochromic flicker
photometry to measure macular pigment optical density
(MPOD). Our aim was to determine the measurement
variability (noise) of the MacuScope.
Methods Thirty-eight normally sighted participants who
ranged in age from 19 to 46 years (25.767.6 years)
were recruited from staff and students of Aston
University. Data were collected by two operators, HB and
JA, in two sessions separated by 1 week in order to
assess test repeatability and reproducibility.
Results The overall mean MPOD for the cohort was
0.4760.14. There was a significant negative correlation
between MacuScope MPOD readings and age
(r¼0.368, p¼0.023). Coefficients were 0.45 and 0.58
for repeatability, and 0.49 and 0.36 for reproducibility. For
each pair of results, there was a significant positive
correlation between mean and difference MPOD values.
Conclusions If MPOD is being monitored over time then
any change less than 0.58 units should not be
considered clinically significant as it is very likely to be
due to instrument noise. The size of the coefficient
appears to be positively correlated with MPOD.
INTRODUCTION
Yellow pigmentation of the macular region was
ﬁrst documented in 1782, and was attributed to the
xanthophyll group of carotenoids much later in
1945.1 Two slightly different chemical structures
have been found, termed lutein (L) and zeaxanthin
(Z).2 It has been suggested that xanthophylls, in the
form of macular pigment (MP) play a similar role in
humans as in plants, as antioxidants and screeners
of high-energy blue light.3 The presence of MP in
the rod outer segments and retinal pigment
epithelium (RPE)4 5 is suggestive of a ROS-
quenching function and the presence of MP in the
inner retinal layers6 supports a photoprotective role.
The absorbance spectrum of MP peaks at 460 nm
and it is purported to act as a broadband ﬁlter,
reducing the sensitivity of the macular region to
short wavelength light which is most damaging in
the 440e460 nm range.7 8
The human retina, and more speciﬁcally the
macula, is the single richest site of carotenoid accu-
mulation within the human body. Post-mortem
retinal analysis has shown that the total L and Z
concentration at the macula is 100 times more than
at the peripheral retina. The assumption that retinal
L and Z is of dietary origin is supported by fundus
photographs of rhesus monkeys on carotenoid-
depleted diets that demonstrate an absence of MP.9
Recently, instruments have been developed for
the measurement of MP optical density (MPOD) in
the clinical environment. These instruments
employ a psychophysical technique called hetero-
chromatic ﬂicker photometry (HFP). One of these
instruments is the MacuScope macular pigment
densitometer (Macuvision Europe Ltd, Solihull,
UK). This is a portable desktop device that requires
subjects to observe ﬂickering stimuli that are
comprised of two alternating wavelengths of light.
One wavelength is absorbed by MP (465 nm) and
one is not (550 nm). During the test, the luminance
ratio of the two wavelengths is reduced until the
ﬂicker is minimised. This minimal ﬂicker point is
recorded by the instrument for one central (where
MP is assumed to be maximal) and one peripheral
(where MP is assumed to be minimal) location. The
ratio of luminance values at these two locations is
then used to calculate the ﬁnal MPOD value.
It is important to determine the measurement
variability, or measurement noise, of the Macu-
Scope in order to be able to identify clinically
signiﬁcant changes in MPOD. This is of particular
interest considering that the MacuScope might be
considered for use in monitoring the effect of
nutritional supplementation or dietary modiﬁca-
tion on MPOD. The aim of this study was to assess
the repeatability and reproducibility of the Macu-
Scope when used in a clinical setting.
MATERIALS AND METHODS
Setting
A clinical practice setting within the Ophthalmic
Research Group, School of Life and Health Sciences
at Aston University, Birmingham, UK.
Study population
Thirty-eight normally sighted participants were
recruited from staff and students of Aston
University. Participants varied in age from 19 to
46 years (25.767.6 years).
Exclusion criteria were: best corrected distance
visual acuity (VA) of more than 0.2 logMAR (VA
was measured under standard testing conditions
using a logMAR chart, retro illuminated to a lumi-
nance of 130 cd/m2 10 (each letter seen was scored
as 0.02 log units, with guessing encouraged)); retinal
disease detected through undilated pupils using
a direct ophthalmoscope; abnormal Amsler grid test
result; glaucoma; lenticular opacities; prescribed
medication associated with changes in retinal
function.
Observation procedures
The same testing room was used for each test for
all data collection sessions. When both eyes met the
inclusion criteria, the right eye was tested; when
only one eye was suitable for inclusion, that eye
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was tested. The test was carried out according to the manu-
facturer ’s instructions.
The eye not being tested was occluded and subjects were
asked to place their forehead in position such that the test eye
was centred on a cross-hair target within the instrument.
Adjustments were made by the operator until the subject
reported the cross-hair target to be clearly in focus. Participants
with astigmatic ametropia or high levels of spherical ametropia
(> 7 D) wore their habitual refractive correction. When the
operator began the test the subject immediately observed the
ﬂickering stimulus, which was centred on the cross-hair target.
Each subject was then asked to ﬁxate the cross-hair target. The
intensity of the ﬂickering target was altered manually by
the operator until the subject reported ‘minimum’ ﬂicker. The
process was repeated with each subject instructed to ﬁxate
a peripheral cross-hair target, and to observe the change in ﬂicker
of the central target using non-foveal retina. Once the point of
minimum ﬂicker is reached for central and peripheral stimuli, the
instrument automatically calculates the MPOD for that eye and
provides a print out of the result.
Data were collected by two operators, HB and JA, in two
sessions separated by 1 week. Prior to the ﬁrst session a trial run
was completed to allow each participant to practice the test. For
the purposes of the study, the operator LCD display of target
intensity was covered to prevent operator bias of the results. In
session one, the ﬁrst test was carried out by JA (JA1) and the
second was carried out by HB (HB1). In session two the ﬁrst test
was carried out by HB (HB2) and the second was carried out by
JA (JA2). This study design permitted assessment of the test
repeatability (HB1 vs HB2 and JA1 vs JA2) and reproducibility
(JA1 vs HB1 and HB2 vs JA2). SPSS for Microsoft Windows XP
software was used for data analysis. Graphs were produced using
SigmaPlot software (version 6) for Microsoft Windows XP.
RESULTS
The four sets of readings (the practice reading was excluded)
were averaged for each subject. The overall mean MPOD for the
cohort was 0.4760.14. The mean individual SD value for the
whole cohort (excluding the practice reading) was 0.1560.011.
There was a signiﬁcant negative correlation between MacuScope
MPOD readings and age (r¼0.368, p¼0.023). The mean MPOD
reading for women (n¼18) was 0.4960.17 and for men (n¼20)
was 0.4560.11. These mean values were not signiﬁcantly
different (t¼0.612, p¼0.545).
Accurate analysis of testeretest data can be achieved using the
coefﬁcient of repeatability.11 12 This gives the 95% conﬁdence
limits for the amount of difference between two sets of results. It
is calculated as 1.96 multiplied by the SD of the mean differences
between the two sets of data. Testeretest results for the four
comparisons are shown in table 1.
The coefﬁcient of repeatability and reproducibility values
indicate the amount of change that can occur between readings
and still be classed as instrument ‘noise’. In other words, using
the worst result of the two for repeatability, our data suggests
that when the same operator is taking repeated MacuScope
readings over time, only increases or decreases in MPOD of more
than 0.58 units can be classed as clinically signiﬁcant (see
ﬁgure 1). Using the worst result of the two for reproducibility, if
two different operators are assessing MPOD with the Macu-
Scope within the same session, only increases or decreases in
MPOD of more than 0.49 units can be classed as clinically
signiﬁcant (see ﬁgure 2).
For each pair of results, there was a signiﬁcant positive
correlation between mean and difference in MPOD values
(JA1eJA2: r¼0.597, p<0.001; HB1eHB2: r¼0.527, p¼0.001;
JA1eHB1: r¼0.470, p¼0.003; HB2eJA2: r¼0.450. p¼0.005). In
other words, the difference between two sets of readings
increased as the MPOD increased. There was no correlation
between the difference between readings represented as
a percentage of the mean MPOD value and the mean MPOD
value for all comparisons except JA1eJA2 (r¼0.402, p¼0.014).
DISCUSSION
We consider our ﬁndings to be useful for eye care practitioners
who use the MacuScope for monitoring of MPOD over time, or
as an outcome measure to assess the effect of dietary modiﬁ-
cation or nutritional supplementation on MPOD. Several large-
scale studies have used HFP techniques for assessment of
MPOD.13e18 Our average MPOD value was 0.4760.14. Other
studies have reported average values in normal cohorts of
0.21160.13 (n¼280, age range: 18e50 years),13 0.2860.21
(n¼280, age range: 18e50 years),14 0.28960.156 (n¼46, age
range: 21e81 years),19 0.319 (n¼100, age range: 22e60 years),15
and 0.4360.23 (n¼1648, age range: 53e86 years).20
Within our cohort there was a signiﬁcant negative correlation
between MPOD reading and age. This relationship has also been
investigated using HFP in other studies; some have reported
a similar relationship,19 21 while others reported no relation-
ship.14 22 23
Our reliability results differ markedly from those found by
another group investigating the use of HFP who reported
a coefﬁcient of reproducibility of 0.08 and a coefﬁcient of
repeatability of 0.09.19 These differences might be explained by
the fact that we used a commercially produced instrument rather
than a laboratory-based instrument designed for research
Table 1 Coefficient of repeatability/reproducibility values for the four
data sets
Repeatability Reproducibility
JA1eJA2 HB1eHB2 JA1eHB1 HB2eJA1
Mean difference 0.019 0.031 0.095 0.082
SD of mean differences 0.23 0.30 0.25 0.18
Coefficient of repeatability/
reproducibility
0.45 0.58 0.49 0.36
Mean MacuscopeTM reading
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Figure 1 Difference in MacuScope reading between HB1 and HB2
compared with the mean (n¼38). The mean bias is represented by the
solid line and the 95% confidence limits are represented by the dashed
lines.
Br J Ophthalmol 2010;94:328e331. doi:10.1136/bjo.2009.167213 329
Clinical science
 group.bmj.com on April 20, 2010 - Published by bjo.bmj.comDownloaded from 
purposes. The authors of this study also state that they took ﬁve
readings on two different occasions (although the method for
assessing reliability was not made clear), and so comparing the
means of repeated readings may have resulted in smaller repro-
ducibility and repeatability coefﬁcients. Our study protocol
permitted a practice run of the test, which we considered to be
reasonable considering that the instrument is designed to be used
in a clinical environment; we were keen to assess the instrument
in a way that would make the results applicable to the clinical
setting. Our ﬁve sets of repeat data were not signiﬁcantly
different when analysed using ANOVA (F¼1.177, p¼0.322),
suggesting no signiﬁcant learning effect. We attribute our rela-
tively large coefﬁcients of repeatability and reproducibility to the
fact that participants found the task conceptually difﬁcult. The
state of ‘minimum ﬂicker ’ is hard to describe (particularly to
naïve subjects) and harder to identify. Participants reported that
trying to identify the central minimum ﬂicker point whilst
ﬁxating on the peripheral target was particularly difﬁcult.
The mean MPOD value found by Beatty et al was
0.28960.156,19 which is lower than our mean value. This may
also go some way to explaining the differences in repeatability
and reproducibility coefﬁcients, as we found a positive correla-
tion between difference and mean MPOD values in our cohort.
When limiting our analysis to subjects with MPOD of less than
0.35, we found markedly different repeatability/reproducibility
coefﬁcients (JA1eJA2: 0.13, n¼13; HB1eHB2: 0.24, n¼9;
JA1eHB1: 0.21, n¼11; HB2eJA2: 0.15, n¼11). This suggests that
the visual task is more difﬁcult with higher MPOD levels,
perhaps because of the higher intensity levels required to mini-
mise ﬂicker in these cases.
There have been no large-scale studies looking at the effect of
L and Z supplementation in MPOD. The results of several small
studies suggest that MPOD can be modiﬁed by nutritional
supplementation and dietary modiﬁcation, but only for some
people. For example, MPOD increased by 4e5% in eight men
supplemented with 10 mg L daily.24 In another study an average
increase in MPOD of 19% was found in people supplemented
with spinach (providing 10.8 mg L and 0.3 mg Z) or sweetcorn
(providing 0.4 mg L and 0.3 mg Z) for up to 15 weeks, although
three out of 13 participants were non-responders.25 Our results
suggest that the MacuScope is not sensitive enough to identify
changes in MPOD of this size. However, the coefﬁcient of
repeatability appears to be reduced for people with lower MPOD
values. The manufacturers of the MacuScope classify ‘low’
MPOD as between 0.1 and 0.28, ‘average’ MPOD as between 0.28
and 0.75, and ‘high’ MPOD as between 0.75 and 1. There were
insufﬁcient subjects in our cohort who measured within the
‘low’ (between one and ﬁve per comparison) or ‘high’ (either two
or three per comparison) categories to allow viable sub-analysis.
The variability of the instrument might be improved if
sensitivity to ﬂicker was assessed for each subject prior to
testing. This process is described by Snodderly et al, and ensures
that the initial test conditions are set according to each subject’s
ﬂicker sensitivity.17
The MacuScope macular pigment densitometer is a MPOD
measurement device designed for use in clinical practice on naïve
subjects. In conclusion, our results suggest that if MPOD is being
monitored over time to assess the effect of an intervention, then
any change less than 0.58 units should not be considered clini-
cally signiﬁcant as it is very likely to be due to instrument noise.
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